{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:48:03Z","timestamp":1772801283502,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Albumin, the most abundant and arguably most important protein in the human body, plays a unique role in decompensated cirrhosis because its structure and function are quantitatively and qualitatively affected. A literature review was performed to provide insights into albumin use. The manuscript was developed using a multidisciplinary approach; 2 hepatologists, a nephrologist, a hospitalist, and a pharmacist, who are all members of or work closely with the Chronic Liver Disease Foundation, collaborated to write this expert perspective review.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Cirrhosis represents the potential end in the spectrum of all chronic liver diseases. Decompensated cirrhosis, defined by the overt manifestation of liver failure (eg, ascites, hepatic encephalopathy, variceal bleeding), is the inflection point associated with increased mortality. Human serum albumin (HSA) infusion serves an important role in the treatment of advanced liver disease. The benefits of HSA administration in patients with cirrhosis are widely accepted, and its use has been advocated by several professional societies. However, inappropriate HSA use can lead to significant adverse patient events. This paper discusses the rationale for the administration of HSA in the treatment of complications of cirrhosis, analyzes the data on the use of HSA in cirrhosis, and streamlines practical recommendations set forth in published guidance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Use of HSA in clinical practice needs to be improved. The objective of this paper is to empower pharmacists to facilitate and improve the use of HSA in patients with cirrhosis at their practice sites.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad070","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T12:53:19Z","timestamp":1680612799000},"page":"806-817","source":"Crossref","is-referenced-by-count":4,"title":["Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis"],"prefix":"10.1093","volume":"80","author":[{"given":"Marcelo","family":"Kugelmas","sequence":"first","affiliation":[{"name":"South Denver Gastroenterology , Englewood, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, North Shore University Hospital, Hempstead, NY, and Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Hempstead, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily J","family":"Owen","sequence":"additional","affiliation":[{"name":"Critical Care, Surgical Burn Trauma Intensive Care Unit, Department of Pharmacy, Barnes-Jewish Hospital , St. Louis, MO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Wadei","sequence":"additional","affiliation":[{"name":"Department of Transplantation, Mayo Clinic , Jacksonville, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Surgery, David Geffen School of Medicine, UCLA , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"9615","key":"2023062312002761300_CIT0001","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"2023062312002761300_CIT0002","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4254\/wjh.v6.i7.504","article-title":"Clinical outcomes of compensated and decompensated cirrhosis: a long term study","volume":"6","author":"Samonakis","year":"2014","journal-title":"World J Hepatol"},{"key":"2023062312002761300_CIT0003","author":"National Institute for Health and Care Excellence."},{"key":"2023062312002761300_CIT0004","author":"Centers for Disease Control and Prevention."},{"issue":"3","key":"2023062312002761300_CIT0005","first-page":"257","article-title":"Albumin as a drug: its biological effects beyond volume expansion","volume":"22","author":"Bihari","year":"2020","journal-title":"Crit Care Resusc"},{"issue":"6","key":"2023062312002761300_CIT0006","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in decompensated cirrhosis: new concepts and perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"issue":"12","key":"2023062312002761300_CIT0007","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41575-018-0045-2","article-title":"Novel perspectives in the management of decompensated cirrhosis","volume":"15","author":"Bernardi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3 Pt 1","key":"2023062312002761300_CIT0008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1172\/JCI101959","article-title":"The use of concentrated human serum albumin in the treatment of cirrhosis of the liver","volume":"27","author":"Kunkel","year":"1948","journal-title":"J Clin Invest."},{"issue":"2","key":"2023062312002761300_CIT0009","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"2023062312002761300_CIT0010","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/lt.26072","article-title":"The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin","volume":"27","author":"Flamm","year":"2021","journal-title":"Liver Transpl"},{"key":"2023062312002761300_CIT0011","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/HMER.S164250","article-title":"Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies","volume":"11","author":"Marciano","year":"2019","journal-title":"Hepat Med"},{"issue":"1","key":"2023062312002761300_CIT0012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1478-3231.2005.01188.x","article-title":"Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail","volume":"26","author":"Moreau","year":"2006","journal-title":"Liver Int"},{"key":"2023062312002761300_CIT0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12876-015-0389-9","article-title":"Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis","volume":"15","author":"Salerno","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"2023062312002761300_CIT0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"issue":"40","key":"2023062312002761300_CIT0015","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.3748\/wjg.v20.i40.14642","article-title":"Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement","volume":"20","author":"Testino","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"9","key":"2023062312002761300_CIT0016","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2023062312002761300_CIT0017","first-page":"301","article-title":"The role and indications of albumin in advanced liver disease","volume":"82","author":"Zaccherini","year":"2019","journal-title":"Acta Gastroenterol Belg"},{"issue":"5","key":"2023062312002761300_CIT0018","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF00263529","article-title":"Albumin abuse in intensive care medicine","volume":"14","author":"Grootendorst","year":"1988","journal-title":"Intensive Care Med"},{"issue":"2","key":"2023062312002761300_CIT0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1054\/clnu.2000.0390","article-title":"Use and abuse of albumin: a survey of clinical records from an internal medicine ward","volume":"20","author":"Finelli","year":"2001","journal-title":"Clin Nutr"},{"issue":"5","key":"2023062312002761300_CIT0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.1991.00400050051011","article-title":"The use of albumin in clinical practice","volume":"151","author":"Erstad","year":"1991","journal-title":"Arch Intern Med"},{"issue":"2","key":"2023062312002761300_CIT0021","first-page":"154","article-title":"Appropriateness of requests for human serum albumin at the University Hospital of Palermo, Italy: a prospective study","volume":"27","author":"Casuccio","year":"2015","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"2023062312002761300_CIT0022","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1751143720961245","article-title":"Human albumin solutions in intensive care: a review","volume":"22","author":"Melia","year":"2021","journal-title":"J Intensive Care Soc"},{"issue":"1","key":"2023062312002761300_CIT0023","first-page":"3","article-title":"The roles we have as hospital pharmacists","volume":"70","author":"Simpson","year":"2017","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"2023062312002761300_CIT0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1060028020935575","article-title":"Clinical pharmacist-led impact on inappropriate albumin utilization and associated costs in general ward patients","volume":"55","author":"Buckley","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2023062312002761300_CIT0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1060028019877471","article-title":"Clinical pharmacist-led impact on inappropriate albumin use and costs in the critically ill","volume":"54","author":"Buckley","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"1 suppl","key":"2023062312002761300_CIT0026","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/00003246-200301001-00003","article-title":"Impact of intensive care unit (ICU) drug use on hospital costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy","volume":"31","author":"Weber","year":"2003","journal-title":"Crit Care Med"},{"key":"2023062312002761300_CIT0027","article-title":"Albumin colloid.","author":"Campos Munoz","year":"2022"},{"issue":"5","key":"2023062312002761300_CIT0028","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","article-title":"Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin","volume":"303","author":"Bhattacharya","year":"2000","journal-title":"J Mol Biol"},{"issue":"3","key":"2023062312002761300_CIT0029","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","article-title":"Human serum albumin: from bench to bedside","volume":"33","author":"Fanali","year":"2012","journal-title":"Mol Aspects Med"},{"issue":"5","key":"2023062312002761300_CIT0030","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1002\/hep.31836","article-title":"Albumin in advanced liver diseases: the good and bad of a drug!","volume":"74","author":"Jagdish","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"2023062312002761300_CIT0031","first-page":"514","article-title":"Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients","volume":"88","author":"Salerno","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"2023062312002761300_CIT0032","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"},{"issue":"5","key":"2023062312002761300_CIT0033","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2013.08.001","article-title":"Effective albumin concentration and cirrhosis mortality: from concept to reality","volume":"59","author":"Jalan","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"2023062312002761300_CIT0034","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.28897","article-title":"Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis","volume":"65","author":"Das","year":"2017","journal-title":"Hepatology"},{"key":"2023062312002761300_CIT0035","doi-asserted-by":"crossref","first-page":"1756284819881302","DOI":"10.1177\/1756284819881302","article-title":"Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization","volume":"12","author":"Bai","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"issue":"10","key":"2023062312002761300_CIT0036","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1097\/01.CCM.0000239119.57544.0C","article-title":"Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study","volume":"34","author":"Dubois","year":"2006","journal-title":"Crit Care Med"},{"key":"2023062312002761300_CIT0037","author":"Centers for Disease Control and Prevention."},{"issue":"17","key":"2023062312002761300_CIT0038","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1056\/NEJM199804233381712","article-title":"A dangerous error in the dilution of 25 percent albumin","volume":"338","author":"Steinmuller","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"2023062312002761300_CIT0039","first-page":"31","article-title":"Cardiovascular dysfunction in patients with liver cirrhosis","volume":"28","author":"Fede","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"2023062312002761300_CIT0040","author":"Prescribers\u2019 Digital Reference."},{"issue":"4","key":"2023062312002761300_CIT0041","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0016-5085(96)70068-9","article-title":"Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis","volume":"111","author":"Gin\u00e8s","year":"1996","journal-title":"Gastroenterology"},{"issue":"4","key":"2023062312002761300_CIT0042","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/jcpt.13461","article-title":"Albumin for cirrhosis-related complications","volume":"46","author":"Erstad","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2023062312002761300_CIT0043","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"2023062312002761300_CIT0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhin.2021.06.003","article-title":"Pharmacist-led education-based antimicrobial stewardship interventions and their effect on antimicrobial use in hospital inpatients: a systematic review and narrative synthesis","volume":"115","author":"Monmaturapoj","year":"2021","journal-title":"J Hosp Infect"},{"issue":"3","key":"2023062312002761300_CIT0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.14218\/JCTH.2015.00015","article-title":"Acute kidney injury in patients with cirrhosis","volume":"3","author":"Russ","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"2023062312002761300_CIT0046","author":"Terlivaz.","year":"2022"},{"key":"2023062312002761300_CIT0047"},{"issue":"2","key":"2023062312002761300_CIT0048","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology"},{"key":"2023062312002761300_CIT0049","author":"Mallinckrodt plc.","year":"13, 2022"},{"issue":"2","key":"2023062312002761300_CIT0050","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"2023062312002761300_CIT0051","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","article-title":"Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013","volume":"60","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"issue":"6","key":"2023062312002761300_CIT0052","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.1840200619","article-title":"Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis","volume":"20","author":"Follo","year":"1994","journal-title":"Hepatology"},{"issue":"3","key":"2023062312002761300_CIT0053","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cgh.2010.11.038","article-title":"Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis","volume":"9","author":"Tandon","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2023062312002761300_CIT0054","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"2023062312002761300_CIT0055","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.510270507","article-title":"Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality","volume":"27","author":"Navasa","year":"1998","journal-title":"Hepatology"},{"issue":"1","key":"2023062312002761300_CIT0056","first-page":"106","article-title":"Acute phase blood proteins: role in the homeostasis and their synthesis induction in the liver","volume":"40","author":"Alekseeva","year":"1994","journal-title":"Fiziol Zh"},{"issue":"6","key":"2023062312002761300_CIT0057","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/1060028020959348","article-title":"Serum albumin levels: who needs them?","volume":"55","author":"Erstad","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2023062312002761300_CIT0058","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A randomized trial of albumin infusions in hospitalized patients with cirrhosis","volume":"384","author":"China","year":"2021","journal-title":"N Engl J Med"},{"key":"2023062312002761300_CIT0059","author":"Albuminex (human albumin) 25%.","year":"2018"},{"issue":"7","key":"2023062312002761300_CIT0060","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2023062312002761300_CIT0061","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/hep.22853","article-title":"Management of adult patients with ascites due to cirrhosis: an update","volume":"49","author":"Runyon","year":"2009","journal-title":"Hepatology"},{"issue":"10138","key":"2023062312002761300_CIT0062","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"2023062312002761300_CIT0063","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sol\u00e0","year":"2018","journal-title":"J Hepatol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad070\/50169622\/zxad070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/13\/806\/50682841\/zxad070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/13\/806\/50682841\/zxad070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T20:54:25Z","timestamp":1687640065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/13\/806\/7102244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":63,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,4,4]]},"published-print":{"date-parts":[[2023,6,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad070","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,4,4]]}}}